- Home
- BCDA vs GNPX Comparison
BCDA vs GNPX Comparison
Compare BCDA & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCDA
- GNPX
- Stock Information
- Founded
- BCDA N/A
- GNPX 2009
- Country
- BCDA United States
- GNPX United States
- Employees
- BCDA N/A
- GNPX N/A
- Industry
- BCDA Biotechnology: Pharmaceutical Preparations
- GNPX Biotechnology: Pharmaceutical Preparations
- Sector
- BCDA Health Care
- GNPX Health Care
- Exchange
- BCDA Nasdaq
- GNPX Nasdaq
- Market Cap
- BCDA 11.3M
- GNPX 10.8M
- IPO Year
- BCDA N/A
- GNPX 2018
- Fundamental
- Price
- BCDA $1.39
- GNPX $9.00
- Analyst Decision
- BCDA Strong Buy
- GNPX
- Analyst Count
- BCDA 1
- GNPX 0
- Target Price
- BCDA $25.00
- GNPX N/A
- AVG Volume (30 Days)
- BCDA 306.5K
- GNPX 1.5M
- Earning Date
- BCDA 11-12-2025
- GNPX 11-12-2025
- Dividend Yield
- BCDA N/A
- GNPX N/A
- EPS Growth
- BCDA N/A
- GNPX N/A
- EPS
- BCDA N/A
- GNPX N/A
- Revenue
- BCDA N/A
- GNPX N/A
- Revenue This Year
- BCDA N/A
- GNPX N/A
- Revenue Next Year
- BCDA N/A
- GNPX N/A
- P/E Ratio
- BCDA N/A
- GNPX N/A
- Revenue Growth
- BCDA N/A
- GNPX N/A
- 52 Week Low
- BCDA $1.00
- GNPX $7.00
- 52 Week High
- BCDA $3.20
- GNPX $157.50
- Technical
- Relative Strength Index (RSI)
- BCDA 42.69
- GNPX 80.32
- Support Level
- BCDA $1.40
- GNPX $0.27
- Resistance Level
- BCDA $1.52
- GNPX $12.97
- Average True Range (ATR)
- BCDA 0.11
- GNPX 0.71
- MACD
- BCDA 0.02
- GNPX 1.11
- Stochastic Oscillator
- BCDA 32.82
- GNPX 68.98
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
About GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.